TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02330926
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00975715
Drug: TRI476
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRI476 oral suspension doses, based on body weight twice daily
Study: NCT00975715
Drug: Placebo to TRI476
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension, taken twice daily
Study: NCT01973816
Drug: Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
Study: NCT01973816
Drug: Cyproterone acetate 50 mg; estradiol 0.5% percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake for 18 months
Study: NCT01973816
Drug: Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake during 24 months
Study: NCT03731832
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be given as a single, oral dose of 4.0 mg weekly (day 1, 8 and 15) for 3 weeks, followed by 1 week without study drug in a 28-day cycle
Study: NCT01001975
Drug: Sunscreen Test Code: V53-028
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
Study: NCT01001975
Drug: Sunscreen Test Code: V53-030
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
Study: NCT01001975
Drug: Standard SPF 4 Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% Homosalate Standard SPF 4 Sunscreen
Study: NCT03731832
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered once daily as an oral dose of 50 mg on cycle days 1 to 21, followed by one week without drug in a 28-day cycle.
Study: NCT03817476
Drug: BI 425809 (Treatment R)
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial formulation 2 tablet (TF2)
Study: NCT01404598
Drug: naproxen 500 mg bid
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 500 mg bid
Study: NCT02005211
Drug: AZD3293
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT02005211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT00377182
Drug: RO5024048 1500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500mg po bid for 4 weeks
Study: NCT00377182
Drug: RO5024048 3000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000mg po bid for 4 weeks
Study: NCT03427632
Drug: Bone Cements
Normalized name: Bone cements
Approvals — FDA: no, EMA: no, PMDA: no
Description: patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
Study: NCT03482011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02607865
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once-daily
Study: NCT01657253
Drug: PRO-148
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instill 1 drop in each eye four times a day, for 60 days
Study: NCT03777696
Drug: placebo to TA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110 ml saline iv
Study: NCT02424071
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04002622
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT03715023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution for inhalation
Study: NCT03715023
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for RSV infection at study site
Study: NCT00995904
Drug: 84ug MAP0020
Approvals — FDA: no, EMA: no, PMDA: no
Description: 84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
Study: NCT00995904
Drug: 42ug MAP0020
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
Study: NCT00995904
Drug: 21ug MAP0020
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
Study: NCT01674712
Drug: Fixed Combination of Fenofibrate/simvastatin 145/20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
Study: NCT01674712
Drug: Simvastatin 20 mg
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
Study: NCT01674712
Drug: Simvastatin 40 mg
Normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
Study: NCT02472275
Drug: Antiandrogen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix
Study: NCT02472275
Drug: Multitargeted Tyrosine Kinase Inhibitor PLX3397
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04295993
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive norepinephrine infusion to maintain mean arterial pressure above 65 mmHg
Study: NCT02331745
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
Study: NCT00575614
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: o.d.
Study: NCT01217905
Drug: AZD7687
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT01970540
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
Study: NCT00151424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched against asenapine and olanzapine
Study: NCT03011528
Drug: VDC-IE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 1 and week 5:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, and week 7:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d
Study: NCT00355615
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT00355615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03933306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.
Study: NCT01614366
Drug: AM 5 + DM 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 5 mg + DMTA07 2.5mg, once daily
Study: NCT01614366
Drug: AM 5 + DM 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 5 mg + DMTA07 7.5mg, once daily
Study: NCT04564846
Drug: ORMD-0801
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg capsules of ORMD-0801 (Oral Insulin)
Study: NCT04804111
Drug: arm 2
Normalized name: Surgitube Arm 2 5/8x50"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of the URC102 group
Study: NCT04804111
Drug: arm 4
Normalized name: cardioplegic 33 (warm 4:1) 40 mEq/500 mL (potassium) PERFUSION PLASTIC BAG, PERFUSION (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 mg
Study: NCT00675714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to be given once a day for up to two years post burn injury.
Study: NCT01704027
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
Study: NCT01724242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04165967
Drug: Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab.~Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing). Actual body weight will be used in calculating the dose of interleukin-2.~Starting Day 14: Nivolumab application 240 mg i.v. over 30 minutes ever 2 weeks with a maximum to 2 years, or until disease progression or inacceptable toxicity.
Study: NCT00707772
Drug: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
Study: NCT00707772
Drug: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
Study: NCT00254657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00126763
Drug: Fentanyl Transdermal Matrix Patch ZR-02-01
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
Study: NCT01620684
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules
Study: NCT01102686
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To eliminate or minimize potential hematologic effects of Pyrimethamine, Leucovorin is to be co-administered with Pyrimethamine at a dose level of 5 mg per day, given when Pyrimethamine is administered.
Study: NCT01598259
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: po 1 hour before bedtime
Study: NCT01381406
Drug: TIO
Normalized name: LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving tiotropium bromide at index within the study period.
Study: NCT02149914
Drug: PPI
Normalized name: PPIase
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01381406
Drug: TIO+FSC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
Study: NCT01211405
Drug: Medium dose MDMA
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg MDMA administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 37.5 mg MDMA 1.5 to 2 hours later
Study: NCT03447249
Drug: VX-659/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received VX-659/TEZ/IVA orally once daily in the morning.
Study: NCT03447249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched VX-659/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
Study: NCT01130246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once daily in addition to atorvastatin and standard of care
Study: NCT00885924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9%
Study: NCT01248936
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00890305
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours).
Study: NCT01420458
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioequivalence of two drug formulations
Study: NCT02929147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Group 3 the PCA will contain placebo.
Study: NCT02792179
Drug: [18F]RO6958948
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of \[18F\]RO6958948 injected will be less than or equal to (\</=) 10 micrograms (µg), injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie \[mCi\]).
Study: NCT03476811
Drug: 0.25% Marcaine at 2ml/hr and pain medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous pain control with OnQ Subcutaneous Drug pump
Study: NCT02133404
Drug: ASP7991
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02133404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04111926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
Study: NCT00619216
Drug: Mycophenolic Acid (Myfortic)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Equimolar conversion from mycophenolate mofetil to mycophenolic acid
Study: NCT02730546
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02730546
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00068601
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of planned chemotherapy regimen
Study: NCT01853020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
Study: NCT01061671
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mgms of simvastatin daily
Study: NCT01061671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo pill daily
Study: NCT02529839
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg/kg on days -5 through -4
Study: NCT00002542
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002542
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002542
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002542
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002542
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02369211
Drug: Acetaminophen (Ofirmev)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs.
Study: NCT00262301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT02704507
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical application nightly for 8 weeks
Study: NCT02704507
Drug: Emollient
Normalized name: Emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application nightly to half the face for 4 weeks
Study: NCT03104829
Drug: DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04002141
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet oral daily
Study: NCT00659802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching dose of Placebo
Study: NCT03609008
Drug: Levcromakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
Study: NCT00632749
Drug: BI 811283 (d1)
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
Study: NCT00482196
Drug: MK0493
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01215344
Drug: DVT prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least one asprin 81 mg per day. Other option per physician's choice
Study: NCT01215344
Drug: Bisphosphonates
Normalized name: Bisphosphonates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
Study: NCT01215344
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 on day 4 of each cycle
Study: NCT06107790
Drug: HS022
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.~The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg
Study: NCT03192176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT03800095
Drug: Early palliative care integration
Approvals — FDA: no, EMA: no, PMDA: no
Description: The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
Study: NCT00002590
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002590
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04806529
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological/Vaccine: A dose of 0.5 mL saline for injection will be administrated to subjects randomized to receive the placebo
Study: NCT02742519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02178098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken once daily
Study: NCT00970658
Drug: Salonsip plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
Study: NCT00970658
Drug: Sabia plaster
Normalized name: Juniperus sabina leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
Study: NCT00957242
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (1mg or 2.5mg)
Study: NCT00584246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 - 150 mg po qhs for 2 months
Study: NCT01519037
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo
Study: NCT01923480
Drug: 15% CLINISOL - Sulfite-free (Amino Acid) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01553058
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection will be given according to the same dose and schedule as the active comparator.
Study: NCT00025324
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04537403
Drug: Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
Study: NCT04537403
Drug: Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart
Study: NCT00753480
Drug: D4064A
Approvals — FDA: no, EMA: no, PMDA: no